Actual rates of stable undetectable minimal residual disease and sustained remission after cessation and calculated rates of overall treatment-free remission for imatinib and estimated rates for second-generation TKIs
NIL indicates nilotinib; and DAS, dasatinib.
*The actual rate.23,24,26
†Estimates based on patients starting with imatinib and then switching over to nilotinib or dasatinib if they do not achieve a deep MR on imatinib. 2A is a conservative estimate of the rates based on the assumption that there are a fixed number of CML patients who will achieve treatment-free remission regardless of which TKI they receive. 2B is the best estimate based on extrapolating figures of stable undetectable minimal residual disease and stable remission after cessation in recently presented trials.20,27,30
‡Estimates based on patients receiving nilotinib or dasatinib frontline. 3A is a conservative estimate of the rates based on the assumption that there are a fixed number of CML patients who will achieve treatment-free remission regardless of which TKI they receive. 3B is the best estimate based on extrapolating figures of stable undetectable minimal residual disease and stable remission after cessation in recently presented trials.12,20,27
